PDS Biotechnology Corporation (PDSB) is a Biotechnology company in the Healthcare sector, currently trading at $1.06. It has a SharesGrow Score of 49/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of PDSB = $476,876.00 (+44988201.9% from the current price, the stock appears undervalued). Analyst consensus target is PDSB = $9 (+749.1% upside).
Valuation: PDSB trades at a trailing Price-to-Earnings (P/E) of -1.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.7.
Net income is $37M (loss), growing at +3.1%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $5.2B against $9M equity (Debt-to-Equity (D/E) ratio 561.21, leveraged). Current ratio is 2.82 (strong liquidity). Debt-to-assets is 17027%. Total assets: $30M.
Analyst outlook: 6 / 7 analysts rate PDSB as buy (86%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 45/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 28/100 (Fail), Future 94/100 (Pass), Income ?/100 (Fail).
